|
Name |
Sphaeropsidin E
|
| Molecular Formula | C20H32O3 | |
| IUPAC Name* |
(1S,2R,4S,4bS,8aS,10R)-2-ethenyl-2,4b,8,8-tetramethyl-3,4,5,6,7,8a,9,10-octahydro-1H-phenanthrene-1,4,10-triol
|
|
| SMILES |
C[C@]12CCCC([C@@H]1C[C@H](C3=C2[C@H](C[C@]([C@@H]3O)(C)C=C)O)O)(C)C
|
|
| InChI |
InChI=1S/C20H32O3/c1-6-19(4)11-13(22)16-15(17(19)23)12(21)10-14-18(2,3)8-7-9-20(14,16)5/h6,12-14,17,21-23H,1,7-11H2,2-5H3/t12-,13+,14+,17-,19+,20+/m1/s1
|
|
| InChIKey |
PEVPTRLNHNJRMF-FKSZAOESSA-N
|
|
| Synonyms |
Sphaeropsidin E; CHEBI:69497; Q27137837; (1S,2R,4S,4bS,8aS,10R)-2-ethenyl-2,4b,8,8-tetramethyl-3,4,5,6,7,8a,9,10-octahydro-1H-phenanthrene-1,4,10-triol
|
|
| CAS | NA | |
| PubChem CID | 10947171 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 320.5 | ALogp: | 2.8 |
| HBD: | 3 | HBA: | 3 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 60.7 | Aromatic Rings: | 3 |
| Heavy Atoms: | 23 | QED Weighted: | 0.641 |
| Caco-2 Permeability: | -4.836 | MDCK Permeability: | 0.00001810 |
| Pgp-inhibitor: | 0.932 | Pgp-substrate: | 0.996 |
| Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.381 |
| 30% Bioavailability (F30%): | 0.016 |
| Blood-Brain-Barrier Penetration (BBB): | 0.501 | Plasma Protein Binding (PPB): | 76.04% |
| Volume Distribution (VD): | 1.826 | Fu: | 26.70% |
| CYP1A2-inhibitor: | 0.021 | CYP1A2-substrate: | 0.154 |
| CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.832 |
| CYP2C9-inhibitor: | 0.061 | CYP2C9-substrate: | 0.177 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.117 |
| CYP3A4-inhibitor: | 0.535 | CYP3A4-substrate: | 0.281 |
| Clearance (CL): | 6.097 | Half-life (T1/2): | 0.068 |
| hERG Blockers: | 0.284 | Human Hepatotoxicity (H-HT): | 0.082 |
| Drug-inuced Liver Injury (DILI): | 0.075 | AMES Toxicity: | 0.034 |
| Rat Oral Acute Toxicity: | 0.98 | Maximum Recommended Daily Dose: | 0.998 |
| Skin Sensitization: | 0.399 | Carcinogencity: | 0.809 |
| Eye Corrosion: | 0.512 | Eye Irritation: | 0.636 |
| Respiratory Toxicity: | 0.985 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002921 | ![]() |
0.472 | D04VIS | ![]() |
0.265 | ||
| ENC002832 | ![]() |
0.376 | D0Y2YP | ![]() |
0.250 | ||
| ENC001070 | ![]() |
0.365 | D0L2LS | ![]() |
0.248 | ||
| ENC002831 | ![]() |
0.363 | D0KR5B | ![]() |
0.245 | ||
| ENC002083 | ![]() |
0.363 | D0Q6NZ | ![]() |
0.245 | ||
| ENC002266 | ![]() |
0.356 | D05BTM | ![]() |
0.243 | ||
| ENC000946 | ![]() |
0.352 | D08SVH | ![]() |
0.243 | ||
| ENC002221 | ![]() |
0.351 | D0T2PL | ![]() |
0.243 | ||
| ENC002923 | ![]() |
0.350 | D04SFH | ![]() |
0.240 | ||
| ENC005921 | ![]() |
0.348 | D0I2SD | ![]() |
0.240 | ||